[go: up one dir, main page]

ECSP11011362A - Anticuerpos contra la proteína tweak humana y usos de los mismos - Google Patents

Anticuerpos contra la proteína tweak humana y usos de los mismos

Info

Publication number
ECSP11011362A
ECSP11011362A EC2011011362A ECSP11011362A ECSP11011362A EC SP11011362 A ECSP11011362 A EC SP11011362A EC 2011011362 A EC2011011362 A EC 2011011362A EC SP11011362 A ECSP11011362 A EC SP11011362A EC SP11011362 A ECSP11011362 A EC SP11011362A
Authority
EC
Ecuador
Prior art keywords
same
antibodies against
tweak protein
human tweak
protein
Prior art date
Application number
EC2011011362A
Other languages
English (en)
Inventor
Ulrich Niewoehner
Hendrik Knoetgen
Monika Baehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP11011362A publication Critical patent/ECSP11011362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpo que se une a la proteína TWEAK, caracterizado por una unión a la proteína TWEAK que se caracteriza porque comprende como dominio variable de cadena pesada una CDR3H seleccionada de entre el grupo que consiste de las secuencias SEC ID nº 8, 16 ó 24.
EC2011011362A 2009-04-02 2011-09-30 Anticuerpos contra la proteína tweak humana y usos de los mismos ECSP11011362A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02

Publications (1)

Publication Number Publication Date
ECSP11011362A true ECSP11011362A (es) 2011-10-31

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011362A ECSP11011362A (es) 2009-04-02 2011-09-30 Anticuerpos contra la proteína tweak humana y usos de los mismos

Country Status (23)

Country Link
US (3) US8093006B2 (es)
EP (2) EP2414398A2 (es)
JP (1) JP5596777B2 (es)
KR (1) KR101344611B1 (es)
CN (1) CN102369219A (es)
AR (1) AR076020A1 (es)
AU (1) AU2010233997A1 (es)
BR (1) BRPI1014867A2 (es)
CA (1) CA2756245A1 (es)
CL (1) CL2011002452A1 (es)
CO (1) CO6362025A2 (es)
CR (1) CR20110462A (es)
EC (1) ECSP11011362A (es)
IL (1) IL214355A0 (es)
MA (1) MA33097B1 (es)
MX (1) MX2011010117A (es)
NZ (1) NZ594347A (es)
PE (1) PE20120577A1 (es)
RU (1) RU2011143903A (es)
SG (2) SG10201404107SA (es)
TW (1) TWI423815B (es)
UA (1) UA105520C2 (es)
WO (1) WO2010115555A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
PH12013500506A1 (en) 2010-10-05 2017-08-23 Hoffmann La Roche Antibodies against human tweak and uses thereof
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
SG11202104463YA (en) * 2018-10-31 2021-05-28 Astellas Pharma Inc Anti-human fn14 antibody
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CN1308451C (zh) 1996-08-07 2007-04-04 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
JP2001513626A (ja) 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2305713A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
JP2003521836A (ja) 1999-03-04 2003-07-15 ビジョン−サイエンシズ・インコーポレイテッド 個別に制御可能な電子シャッター回路を備えた画像センサユニットセル
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
WO2001030429A1 (en) 1999-10-22 2001-05-03 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
CA2408228A1 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1997512B1 (en) 2002-04-09 2013-12-04 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
DK2332408T3 (da) 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
ZA200707489B (en) 2005-03-07 2008-12-31 Genentech Inc Methods and compositions for modulating tweak and FN14 activity
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
SG175005A1 (en) 2011-11-28
AU2010233997A1 (en) 2011-08-18
NZ594347A (en) 2012-09-28
MX2011010117A (es) 2011-10-14
SG10201404107SA (en) 2014-10-30
AR076020A1 (es) 2011-05-11
US20120083015A1 (en) 2012-04-05
IL214355A0 (en) 2011-09-27
RU2011143903A (ru) 2013-05-10
EP2597104A1 (en) 2013-05-29
WO2010115555A3 (en) 2011-01-06
US8852887B2 (en) 2014-10-07
TWI423815B (zh) 2014-01-21
BRPI1014867A2 (pt) 2016-04-12
JP2012521771A (ja) 2012-09-20
CR20110462A (es) 2011-09-21
CA2756245A1 (en) 2010-10-14
EP2414398A2 (en) 2012-02-08
JP5596777B2 (ja) 2014-09-24
PE20120577A1 (es) 2012-05-23
US8883976B2 (en) 2014-11-11
CL2011002452A1 (es) 2012-03-23
WO2010115555A2 (en) 2010-10-14
UA105520C2 (uk) 2014-05-26
US20120207750A1 (en) 2012-08-16
CO6362025A2 (es) 2012-01-20
US20100255008A1 (en) 2010-10-07
KR101344611B1 (ko) 2013-12-30
MA33097B1 (fr) 2012-03-01
US8093006B2 (en) 2012-01-10
KR20110122868A (ko) 2011-11-11
CN102369219A (zh) 2012-03-07
TW201039847A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
ECSP11011362A (es) Anticuerpos contra la proteína tweak humana y usos de los mismos
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
PE20121616A1 (es) Anticuerpos anti-her3
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
AR075604A1 (es) Anticuerpos contra un ligando que induce proliferacion (april)
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
CR9819A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
ES2667568T3 (es) Anticuerpo anti-B7-H3
CO6331296A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
MX343640B (es) Promotor de osteogenesis.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201370081A1 (ru) Антитела к cd48 и их применение
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
CO6650372A2 (es) Proteínas de unión de dominio variable dual que se unen a tnfy tweak, y métopdos para hacer y usar dichas proteínas
PE20131411A1 (es) Anticuerpos contra la tweak humana y usos de los mismos